DanielYingWangMD

PubMed

• 8 citations
  A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
  Hyun-Sung Lee, Hee-Jin Jang, Maheshwari Ramineni, Daniel Y Wang, Daniela Ramos, Jong Min Choi, Taylor Splawn, Monica Espinoza, Michelle Almarez, Leandria Hosey, Eunji ...> ;Clinical Cancer Research. 2023 Feb 1
• 8 citations
  Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access.
  Marcus A Florez, Jan O Kemnade, Nan Chen, Wendy Du, Anita L Sabichi, Daniel Y Wang, Quillan Huang, Courtney N Miller-Chism, Aparna Jotwani, Albert C Chen, David Hernan...> ;Cancer Research Communications. 2022 Jul 26
• 5 citations
  Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment.
  Hee-Jin Jang, Hyun-Sung Lee, Wendong Yu, Maheshwari Ramineni, Cynthia Y Truong, Daniela Ramos, Taylor Splawn, Jong Min Choi, Sung Yun Jung, Ju-Seog Lee, Daniel Y Wang,...> ;Cancer Research. 2022 Jul 18
• 12 citations
  Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant Mesothelioma.
  Hee Jin Jang, Cynthia Y. Truong, Eric M. Lo, Hudson M. Holmes, Daniela Ramos, Maheshwari Ramineni, Ju Seog Lee, Daniel Y. Wang, Massimo Pietropaolo, R. Taylor Ripley, ...> ;The Annals of Thoracic Surgery. 2021 Sep 27
• 13 citations
  Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy.
  Helen Dearden, Lewis Au, Daniel Y. Wang, Lisa Zimmer, Zeynep Eroglu, Jessica Smith, Marcello Cuvietto, Chloe Khoo, Victoria Atkinson, Serigne Lo, Georgina V. Long, Sha...> ;European Journal of Cancer. 2021 Jun 25
• 21 citations
  Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
  Jamie S. Lin, Daniel Y Wang, Omar Mamlouk, William F. Glass, Maen Abdelrahim, Cassian Yee, Ala Abudayyeh> ;Journal for Immunotherapy of Cancer. 2020 Oct 1
• 42 citations
  Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
  Meghan J. Mooradian, Daniel Y. Wang, Melissa A. Lumish, Tianqi Chen, Anita Giobbie-Hurder, Douglas B. Johnson, Ryan J. Sullivan, Michael Dougan> ;Journal for Immunotherapy of Cancer. 2020 May 1
• 11 citations
  Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis
  Hazem E El-Osta, Frank E. Mott, Bryan M. Burt, Daniel Y. Wang, Anita L. Sabichi> ;Oncoimmunology. 2019 Sep 20
• 18 citations
  Anti-PD-1-induced pneumonitis is associated with persistent imaging abnormalities in melanoma patients
  Douglas B. Johnson, Kevin B. Taylor, Justine V. Cohen, Noura Ayoubi, Alexandra M Haugh, Daniel Y. Wang, Brian D. Schlick, Amber L. Voorhees, Kenneth L. Gage, Florian J...> ;Cancer Immunology Research. 2019 Aug 28
• 112 citations
  A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
  Douglas B. Johnson, Wyatt J. McDonnell, Paula I. Gonzalez-Ericsson, Rami N. Al-Rohil, Bret C. Mobley, Joe-Elie Salem, Daniel Y. Wang, Violeta Sanchez, Yu Wang, Cody A....> ;Nature Medicine. 2019 Jul 22
• 16 citations
  Correlates of response and outcomes with talimogene laherperpvec.
  Alice Zhou, Daniel Y. Wang, Svetlana B. McKee, Fei Ye, Chun‐Che Wen, Debbie E. Wallace, Kristin K. Ancell, Robert M. Conry, Douglas B. Johnson> ;Journal of Surgical Oncology. 2019 Jul 2
• 37 citations
  Clinical characterization of colitis arising from anti-PD-1 based therapy
  Daniel Y. Wang, Meghan J. Mooradian, Dae Won Kim, Neil J. Shah, Sarah E. Fenton, Robert M. Conry, Rutika Mehta, Ann W. Silk, Alice Zhou, Margaret L. Compton, Rami N. A...> ;Oncoimmunology. 2019 Jan 2
• 19 citations
  Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.
  Elizabeth J. Davis, Matthew C. Perez, Noura Ayoubi, Shilin Zhao, Fei Ye, Daniel Y. Wang, Jeffrey A. Sosman, Rami N. Al-Rohil, Zeynep Eroglu, Douglas B. Johnson> ;Journal of Immunotherapy. 2019 Jul 1
• 102 citations
  Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.
  Douglas B. Johnson, Mellissa J. Nixon, Yu Wang, Daniel Y. Wang, Emily Castellanos, Monica V. Estrada, Paula I. Ericsson-Gonzalez, Candace H Cote, Roberto Salgado, Viol...> ;JCI Insight. 2018 Dec 20
• Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.
  Saab, K. R.,Mooradian, M. J.,Wang, D. Y.,Chon, J.,Xia, C. Y.,Bialczak, A.,Abbate, K. T.,Menzies, A. M.,Johnson, D. B.,Sullivan, R. J.,Shoushtari, A. N.> ;Cancer. 2018 Dec 07
• 210 citations
  Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
  Curtis H. Kugel, Stephen M. Douglass, Marie R. Webster, Amanpreet Kaur, Qin Liu, Xiangfan Yin, Sarah A. Weiss, Farbod Darvishian, Rami N. Al-Rohil, Abibatou Ndoye, Ree...> ;Clinical Cancer Research. 2018 Nov 1
• Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
  Wang, D. Y.,Salem, J. E.,Cohen, J. V.,Chandra, S.,Menzer, C.,Ye, F.,Zhao, S.,Das, S.,Beckermann, K. E.,Ha, L.,Rathmell, W. K.,Ancell, K. K.,Balko, J. M.,Bowman, C.,Dav...> ;JAMA Oncol. 2018 Sep 23
• 412 citations
  Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multic...
  Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess, Carmen Mak, Daniel Y. Wang, Rajat Rai, John J. Park, Lauren E. Haydu, Christine N. Spencer, Matthew Wongchenko,...> ;The Lancet. Oncology. 2018 Mar 1
• 67 citations
  Toxicities Associated With PD-1/PD-L1 Blockade.
  Daniel Y. Wang, Douglas B. Johnson, Elizabeth J. Davis> ;Cancer Journal. 2018 Jan 1
• 129 citations
  Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.
  Daniel Y. Wang, Fei Ye, Shilin Zhao, Douglas B. Johnson> ;Oncoimmunology. 2017 Aug 14
• 3 citations
  Immunotherapy: Who Is Eligible?
  Daniel Wang, Jill Gilbert, Young J. Kim> ;Otolaryngologic Clinics of North America. 2017 Aug 1
• When to consider alternatives to front-line immune therapies in metastatic melanoma
  Daniel Y. Wang, Douglas B. Johnson> ;Melanoma Management. 2017 May 10
• 36 citations
  Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.
  Wang, D. Y., Wang, D. Y., Eroglu, Z., Eroglu, Z., Ozgun, A., Ozgun, A., Leger, P. D., Leger, P. D., Zhao, S., Zhao, S., Ye, F., Ye, F., Luke, J. J., Luke, J. J., Josep...> ;Cancer immunology research. 2017 Apr 12
• Cardiovascular Toxicities Associated with Cancer Immunotherapies
  Javid J. Moslehi, Daniel Y. Wang, Douglas B. Johnson> ;Current Cardiology Reports. 2017 Feb 22
• 19 citations
  Rising Incidence of Colorectal Cancer Among Young Hispanics in Texas.
  Daniel Y. Wang, Aaron P. Thrift, Neda Zarrin-Khameh, Alexandra Wichmann, Georgina Armstrong, Patricia A. Thompson, Melissa L. Bondy, Benjamin L. Musher> ;Journal of Clinical Gastroenterology. 2017 Jan 1
• Join now to see all

Journal Articles

• Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-cell Populations  
  Zeynep Eroglu, Iman Osman, Theodore S Nowicki, Antoni Ribas, Michael A Davies, Farbod Darvishian, Daniel Y Wang, Douglas B Johnson, Ravi K Amaravadi, Clinical Cancer Research

Lectures

• Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM). 
  2019 ASCO Annual Meeting - 6/1/2019